What molecular alterations lead to neurological disease or affect management/prognosis?
- Excitation–contraction uncoupling (e.g., channelopathies)
- Dysfunctional volume regulation (e.g., cytotoxic edema)
- Altered membrane excitability (e.g., epilepsy)
- Conduction abnormalities (e.g., demyelinating conditions)
- Oxidative stress (e.g., mitochondrial disorders)
- Autoimmune attack of receptors (e.g., myasthenia gravis)
